Treating Acute Leukemias
in Europe

Bridging Science and Practice: From Newest Clinical Approaches to Real-World Clinical Cases


This 2-day virtual program offers a comprehensive overview of the latest clinical updates and novel treatment strategies for acute leukemia, presented by experts. Attendees will have the opportunity to gain knowledge on optimal treatment of patients with leukemia, join patient case-based discussions, and interact with experts.

Date and Location

November 16-17, 2023, Webinar

Meeting Content

View the slides and watch the video of Day 1

View the slides and watch the video of Day 2


Elias Jabbour

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

Naval Daver

Naval Daver, MD

MD Anderson Cancer Center, Houston, TX, USA


Nicola Gokbuget

Nicola Gökbuget, MD

University Hospital Frankfurt, Germany

José Maria Ribera

Josep-Maria Ribera, MD, PhD

Catalan Institute of Oncology, University Hospital Germans Trias i Pujol,

Charles Craddock

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil

Queen Elizabeth Hospital, Birmingham, United Kingdom

Stephane De Botton

Stéphane de Botton, MD, PhD

Gustave Roussy Cancer Center
Paris, France


This 2-day interactive virtual meeting with global experts will focus on the treatment of patients with acute leukemia in various countries within Europe.

Day 1: Follow interactive presentations and case-based discussions on the latest updates for ALL and AML, including the role of MRD, risk stratification, and long-term safety considerations, and engage with the faculty in panel discussions on optimal treatment, patient access, and regional challenges across Europe.

Day 2: Join to learn more about current approaches for relapsed ALL and AML, considerations for AYA ALL management (including case-based discussions), and the evolving role of transplantation, and interact with faculty during a panel discussion on how first-line therapy influences subsequent treatment.

Day 1: Plenary Sessions

Thursday, November 16, 2023

11.00 – 14.00 (UTC -6) Houston time
18.00 – 21.00 (UTC +1) Amsterdam

Time (UTC +1) Topic Presenter
18.00 – 18.10 Welcome and meeting overview; introduction to the voting system Elias Jabbour
18.10 – 18.25 Review of prognostic value of MRD in ALL and AML Josep-Maria Ribera
18.25 – 18.40 Latest achievements in ALL and AML developments Elias Jabbour
18.40 – 18.55 AYA ALL patients – what is the current treatment approach for this diverse patient population? Special considerations for adolescents and young adults and how we can use this experience in adult patients Nicola Gökbuget
18.55 – 19.25

ALL case-based panel discussion

  • Case ALL (10 min)
  • Case ALL AYA (10 min)
  • Discussion (10 min) – panelists: all faculty
Elias Jabbour and all faculty
19.25 – 19.35 Break  
19.35 – 19.50 Genetic characterization and risk stratification of AML Stéphane de Botton
19.50 – 20.05 Therapeutic approaches in high-risk and frail AML patients Naval Daver
20.05 – 20.20 Maintenance and time-limited treatment strategies in ALL and AML Josep-Maria Ribera
20.20 – 20.50 Panel discussion: Open questions in ALL and AML – regional specificities (1 trigger slide per country) Elias Jabbour and all faculty
20.50 – 21.00 Session close Elias Jabbour

Day 2: Plenary Sessions

Friday, November 17, 2023

11.00 – 14.15 (UTC -6) Houston time
18.00 – 21.15 (UTC +1) Amsterdam

Time (UTC +1) Topic Presenter
18.00 – 18.10 Welcome to Day 2 Elias Jabbour
18.10 – 18.25 Frontline approaches and the role of genetic variants in ALL – Ph+ and Ph-like Elias Jabbour
18.25 – 18.45 Current treatment options for relapsed ALL in adult and elderly patients Josep-Maria Ribera
18.45 – 19.05 Current treatment options for relapsed AML in adult and elderly patients Charles Craddock
19.05 – 19.35

AML case-based panel discussion

  • Case AML: young, high risk (10 min)
  • Case AML: elderly (10 min)
  • Discussion  (10 min)
Elias Jabbour and all faculty
19.35 – 19.45 Break  
19.45 – 20.05 Long-term safety considerations for AML and ALL Stéphane de Botton
20.05 – 20.35

Current and future role of transplantation in acute leukemias (including regional insights)

  • AML – Charles Craddock (10 min)
  • ALL – Nicola Gökbuget (10 min)
  • Discussion (10 min)
Charles Craddock and Nicola Gökbuget
20.35 – 21.05

Panel discussion: How treatment in first-line influences further treatment approach in ALL and AML

  • Will CAR T and bispecifics change the landscape?
  • Role of HSCT – is it still confirmed?
  • What does the future look like?
Elias Jabbour and all faculty
21.05 – 21.15 Session close Elias Jabbour